Compare · CGIX vs ELV
CGIX vs ELV
Side-by-side comparison of Cancer Genetics, Inc. (CGIX) and Elevance Health Inc. (ELV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGIX and ELV operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV carries a market cap of $90.81B.
- ELV has hit the wire 3 times in the past 4 weeks while CGIX has been quiet.
- ELV has more recent analyst coverage (23 ratings vs 0 for CGIX).
- Company
- Cancer Genetics, Inc.
- Elevance Health Inc.
- Price
- -
- $418.31+0.63%
- Market cap
- -
- $90.81B
- 1M return
- -
- +12.19%
- 1Y return
- -
- +7.35%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- n/a
- News (4w)
- 0
- 3
- Recent ratings
- 0
- 23
ELV
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest CGIX
- SEC Form 4: John R Fletcher was granted 8,676 units of Common Stock
- SEC Form 4 filed by Marcus Boehm
- SEC Form 4 filed by Joanna Horobin
- SEC Form 4 filed by Howard Mcleod
- SEC Form 4 filed by Yung-Ping Yeh
- SEC Form 4 filed by R. Paul Hansen
- SEC Form 4 filed by E. Geoffrey Harris
- SEC Form 4 filed by Ralf Brandt
- SEC Form 4 filed by D.C. Andrew Lafrence
- SEC Form 4 filed by A John Roberts
Latest ELV
- Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
- CAO & Controller Penczek Ronald W exercised 1,531 shares at a strike of $294.30 and sold $617,192 worth of shares (1,531 units at $403.13) (SEC Form 4)
- Elevance Health upgraded by Deutsche Bank with a new price target
- Director Schulman Amy W was granted 563 shares, increasing direct ownership by 258% to 781 units (SEC Form 4)
- Director Schneider Ryan M. was granted 563 shares, increasing direct ownership by 9% to 7,163 units (SEC Form 4)
- Director Peru Ramiro G was granted 563 shares, increasing direct ownership by 6% to 9,908 units (SEC Form 4)
- Director Neri Antonio F was granted 563 shares, increasing direct ownership by 11% to 5,488 units (SEC Form 4)
- Director Jallal Bahija was granted 563 shares, increasing direct ownership by 12% to 5,351 units (SEC Form 4)
- Director Hay Lewis Iii was granted 563 shares, increasing direct ownership by 5% to 12,070 units (SEC Form 4)
- Director Dixon Robert L Jr was granted 563 shares, increasing direct ownership by 5% to 10,885 units (SEC Form 4)